Business Context and Reporting Period
Company: Capricor Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date: July 15, 2019
Context: The filing serves as a Regulation FD disclosure to provide an update on the top-line interim results of the HOPE-2 clinical trial. The update was delivered via a slide presentation attached as Exhibit 99.1.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is strictly a disclosure of clinical trial updates.
Material Changes
The material event reported is the release of interim results for the HOPE-2 clinical trial. No financial changes or comparative period data are included in this specific filing.
Guidance, Outlook, and Risks
Management Commentary: The Company provided an update on the HOPE-2 trial results through a slide presentation available on its investor website and attached to this filing.
Legal Disclaimer: The information in this Form 8-K and Exhibit 99.1 is furnished and shall not be deemed "filed" under Section 18 of the Exchange Act. It is not subject to the liabilities of that section and will not be incorporated by reference into Securities Act filings unless expressly referenced.
Investor Verification Checklist
- Review the attached slide presentation (Exhibit 99.1) for specific HOPE-2 trial data points.
- Verify the clinical trial results on the "Investors" section of the Company's website (www.capricor.com).
- Confirm that this filing does not constitute a formal financial report or contain audited financial data.